Abstracts tagged "hydroxychloroquine and systemic lupus erythematosus (SLE)"

Abstract Number: 318 • 2019 ACR/ARP Annual Meeting
Improving Safe Prescribing of Hydroxychloroquine in a Safety Net Hospital Rheumatology Clinic
Francine Castillo¹, Michael Dodge ¹, Jung Hee Noh ², Laura Trupin ¹, Jinoos Yazdany ³ and Sarah Goglin ³, ¹University of California, San Francisco, San Francisco, CA, ²Zuckerberg San Francisco General Hospital, San Francisco, CA, ³UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: Hydroxychloroquine (HCQ) prescribing is standard of care for patients with SLE. The main potential side effect is retinal toxicity, especially at higher doses and…
Abstract Number: 1181 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine: Do We All See Eye to Eye? a Single-Site Analysis of Hydroxychloroquine Dosing Compared to 2016 American Academy of Ophthalmology Guidelines
Vaneet K. Sandhu¹, Noopur Goel² and Jamileh Hanna², ¹Division of Rheumatology, Loma Linda University, Loma Linda, CA, ²Loma Linda University, Loma Linda, CA
Background/Purpose: Hydroxychloroquine is universally recommended to treat patients with SLE, stressing the importance of appropriate dosing. The 2016 American Academy of Ophthalmology (AAO) guidelines recommend…
Abstract Number: 1382 • 2018 ACR/ARHP Annual Meeting
Evaluating Results of an Interferon-γ Release Assay in Patients with Autoimmune Skin Disease on Hydroxychloroquine
Rebecca Gaffney¹ and Victoria P. Werth², ¹Dermatology, University of Pennsylvania, Philadelphia, PA, ²Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: QuantiFERON-TB Gold is commercial interferon-γ release assay used to screen patients for tuberculosis before starting or while on immunosuppressive therapies. Clinical studies on efficacy…
Abstract Number: 2628 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine and Prednisone Have Different Effects on Antiphospholipid Antibodies in SLE, with Hydroxychloroquine Not Reducing IgA Anticardiolipin
Michelle Petri¹, Mertcan Avci² and Laurence S Magder³, ¹Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ²Medicine, Istanbul Faculty of Medicine, Istanbul, Turkey, ³Epidemiology and Public Health, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Antiphospholipid antibodies in SLE may be changed by treatment, but past studies have been conflicting. We examined the impact of starting or stopping two…
Abstract Number: 2631 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine Blood Levels Are Significantly Associated with Cardiovascular Risk Factors
Michelle Petri¹, Daniel Goldman¹ and Laurence S Magder², ¹Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ²Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: In studies of SLE patients, the benefits of hydroxychloroquine (HCQ) extend beyond control of disease activity. In particular, HCQ use has decreased multiple cardiovascular…
Abstract Number: 2634 • 2018 ACR/ARHP Annual Meeting
The Risk of Hydroxychloroquine Retinopathy in an SLE Cohort: Screening and Prevention in Clinical Practice
Caroline Siegel¹, Jennifer M. Grossman², John Fitzgerald³, Bevra H Hahn⁴, Sarah Chen⁵, Lori Sahakian⁴, Eloise Olmos², Michael B. Gorin⁶ and Maureen A. McMahon², ¹Department of Internal Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ³Medicine-Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁴UCLA David Geffen School of Medicine, Los Angeles, CA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Department of Ophthalmology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used medication for SLE because of its highly favorable risk-benefit ratio. Drug-induced retinopathy is one of very few serious…
Abstract Number: 2637 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine Improves Disease Activity and Allows Reduction of Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus
Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa and Kimito Kawahata, Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Hydroxychloroquine (HCQ) was not approved in Japan until 2015 and its therapeutic potential remains poorly understood in the population. In this study, we evaluated…
Abstract Number: 2582 • 2017 ACR/ARHP Annual Meeting
Compliance and Persistence with Hydroxychloroquine in Patients with Systemic Lupus Erythematosus
Seong-Min Kweon¹, Seung-Geun Lee², Ji-Heh Park², Eun-Kyoung Park³, Yun-Kyung Kim⁴, Geun-Tae Kim⁵ and Dong Hyun Sohn⁶, ¹Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, South Korea, Busan, Korea, Republic of (South), ²Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea, Republic of (South), ⁴Internal Medicine, Kosin University College of Medicine, Busan, South Korea, Busan, Korea, Republic of (South), ⁵Kosin University College of Medicine, Busan, Korea, Republic of (South), ⁶Microbiology and Immunology, Pusan National University School of Medicine, Yangsan, Korea, Republic of (South)
Compliance and persistence with hydroxychloroquine in patients with systemic lupus erythematosusBackground/Purpose: Lifelong treatment with hydroxychloroquine (HCQ) is now recommended for all patients with systemic lupus…
Abstract Number: 2599 • 2017 ACR/ARHP Annual Meeting
Efficacy and Toxicity of Antimalarials in Systematic Lupus Erythematosus: A Systematic Review
Gaurav Sharma¹, Jasvinder A. Singh², Mohammed Sohaib Khaleel³ and Shristi Shrestha⁴, ¹Department of Medicine, Division of Immunology and Rheumatology, UAB School of Medicine, Birmingham, AL, ²Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Department of Molecular Cardiology, University of Louisville, Louisville, KY, ⁴Internal Medicine, Kathmandu Medical College Teaching Hospital, Kathmandu, Nepal
Background/Purpose: To determine the efficacy and adverse effects of antimalarials in patients with systematic lupus erythematosus (SLE). Methods: A literature search from inception to December…
Abstract Number: 755 • 2016 ACR/ARHP Annual Meeting
Hydroxychloroquine Blood Level Monitoring in a Predominantly Hispanic Systemic Lupus Erythematosus Cohort
James Miceli¹, Kayla Neville¹, Laura Geraldino-Pardilla² and Anca D. Askanase³, ¹Rheumatology, Columbia University Medical Center, New York, NY, ²Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ³Department of Medicine, Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Hydroxychloroquine (HCQ) is recommended for all patients with SLE. While patient reported adherence rates are between 51-64%, blood HCQ level testing may be a…
Abstract Number: 1782 • 2015 ACR/ARHP Annual Meeting
a Double-Blind, Randomized, Parallel-Group Study of Hydroxychloroquine on Cutaneous Lupus Erythematosus in Japan
Naoto Yokogawa¹, Toshiya Takahashi², Toshiaki Sato³ and Naohisa Yokota⁴, ¹on behalf of Japanese Hydroxychloroquine Study Group, Japan, Japan, ²Sanofi K.K., Tokyo, Japan, ³Sanofi.KK, Tokyo, Japan, ⁴Sanofi KK, Tokyo, Japan
Background/Purpose: In Japan hydroxychloroquine (HCQ) is still unavailable due to the banning of chloroquine in 1974 following allegations that it caused severe retinopathy. Therefore, a…
Abstract Number: 1802 • 2015 ACR/ARHP Annual Meeting
Hydroxychloroquine Level Variants and Predictors in a Connective Tissue Disease Population
Ann Biehl¹, Maryam Ghaderi-Yeganeh², Zerai Manna³, Abhijit Dasgupta⁴, Mariana J. Kaplan⁵ and Sarfaraz Hasni³, ¹Department of Pharmacy, National Institutes of Health Clinical Center, Bethesda, MD, ²National Institutes of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴National Institutes of Arthritis, Musculoskeletal and Skin Diseases,, National Institutes of Health, Bethesda, MD, ⁵Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Hydroxychloroquine (HCQ) dose adjustment in patients with impaired renal function has been suggested to prevent toxicity. However, evidence to support this practice is scant. …
Abstract Number: 1925 • 2014 ACR/ARHP Annual Meeting
Determinants of Blood Hydroxychloroquine Concentration Variations in Systemic Lupus Erythematosus Patients
Moez Jallouli¹, Lionel Galicier², Olivier Aumaître³, Camille Francès⁴, Véronique Le-Guern⁵, F. Lioté⁶, Amar Smail⁷, Nicolas Limal⁸, L. Perard⁹, H. Desmurs-Clavel¹⁰, Du Boutin¹¹, B. Asli¹², Jean Emmanuel Kahn¹³, Jacques Pourrat¹⁴, Laurent Sailler¹⁵, F. Ackermann^1,13, T. Papo¹⁶, Karim Sacre¹⁷, O. Fain¹⁸, J. Stirnemann¹⁸, Patrice Cacoub¹⁹, Gaëlle Leroux²⁰, Judith Cohen-Bittan²¹, Js Hulot²², Zahir Amoura²³, Jean-Charles Piette²⁴ and Nathalie Costedoat-Chalumeau²⁵, ¹Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ²Internal Medicine, Hopital St Louis, AP-HP, Paris, France, ³Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont–Ferrand, Clermont–Ferrand, France, ⁴service de dermatologie allergologie, Hôpital Tenon, Paris Cedex 20, France, ⁵service de médecine interne, Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁶service de rhumatologie, Hôpital Lariboisière, Université Paris-Diderot, Sorbonne Paris-Cité, Paris, France, ⁷Internal Medicine Department, CHU Amiens Nord, Amiens, France, ⁸Department of Internal Medicine, Hôpital Henri Mondor, APHP, Creteil, France, ⁹service de médecine interne, Hospices Civils de Lyon, groupement Hospitalier Edouard Herriot, Lyon, France, ¹⁰service de médecine interne, Hospice civils de Lyon, Lyon, France, ¹¹Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ¹²Departement of clinical immunology, Hopital Saint Louis, Université Paris Diderot, Sorbonne Paris Cité, Paris, France, ¹³internal medicine, Hopital Foch, Suresnes, France, ¹⁴nephrolohy, CHU Toulouse, Hopital Rangueil, University of Paul Sabatier, Toulouse, France, ¹⁵Service de Médecine Interne, S, CHU Toulouse, Hopital Purpan, University of Paul Sabatier, Toulouse, France, ¹⁶Internal Medicine, Hopital Bichat Claude Bernard, University of Paris Diderot, Sorbonne Paris cité, Paris, FL, France, ¹⁷Internal Medicine, University Paris-7, INSERM U699, APHP, Bichat Hospital, Paris, France, ¹⁸Internal Medicine, Hopital Jean Verdier, University Paris Nord, Sorbonne Paris Cité, Paris, France, ¹⁹Department of Internal Medicine 2., CHU Pitié-Salpêtrière, Paris, France, ²⁰Department of Internal Medicine 1, CHU Pitié-Salpêtrière, Paris, France, ²¹Service de medecine gériatrique, CHU Pitié-Salpêtrière, Paris, France, ²²Pharmacology, CHU Pitié-Salpêtrière, UPMC, University Paris 6, Paris, France, ²³Internal medicine 2, French National Reference Center for Systemic Lupus and Antiphospholipid Syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ²⁴Department of Internal Medicine 1., CHU Pitié-Salpêtrière, Paris, France, ²⁵Internal Medicine, Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: Hydroxychloroquine (HCQ) is now recognized as an important treatment of systemic lupus erythematosus (SLE). Blood HCQ levels ([HCQ]) can be quantified by high performance…
Abstract Number: 1805 • 2013 ACR/ARHP Annual Meeting
Hydroxychloroquine Levels Identify Four Distinct Subsets of Systemic Lupus Erythematosus Patients
Michelle Petri, Hong Fang and William Clarke, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Hydroxychloroquine is used for both its effect on SLE disease activity (cutaneous and arthritis) and for its preventive roles (reduction in flares, renal damage,…
Abstract Number: 1806 • 2013 ACR/ARHP Annual Meeting
Association Between Hydroxychloroquine Exposure and Incidence Of Diabetes Mellitus In Systemic Lupus Erythematosus
Michelle Petri¹ and Laurence S. Magder², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD
Background/Purpose: Diabetes mellitus is one of the SLICC/ACR Damage Index items and a recognized risk factor for cardiovascular disease and renal failure. In rheumatoid arthritis,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].